Johnson & Johnson $JNJ Stock Holdings Trimmed by Korea Investment CORP

Key Points

• Korea Investment CORP cut its Johnson & Johnson stake by 6.5% in the second quarter, selling 128,160 shares and retaining 1.85 million shares worth approximately $469.8 million. Institutional investors collectively own 69.55% of JNJ.
• Analysts maintain a generally positive outlook, with JNJ carrying a consensus “Moderate Buy” rating and an average price target of $272.83; individual targets range as high as $300, while UBS later initiated coverage with a $320 target.
• Johnson & Johnson exceeded quarterly expectations, reporting $2.90 in EPS and $25.31 billion in revenue, up 6.6% year over year. The company also declared a $1.34 quarterly dividend, equivalent to a 1.9% yield at the reported share price.

Korea Investment CORP lessened its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,849,714 shares of the company's stock after selling 128,160 shares during the period. Johnson & Johnson comprises 0.9% of Korea Investment CORP's portfolio, making the stock its 15th largest position. Korea Investment CORP owned 0.08% of Johnson & Johnson worth $469,772,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in JNJ. Silver Coast Investments LLC lifted its stake in Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV increased its stake in Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares during the last quarter. Denali Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.2% during the second quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock worth $839,000 after purchasing an additional 40 shares during the period. Sierra Capital LLC lifted its position in shares of Johnson & Johnson by 0.5% in the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock worth $1,685,000 after buying an additional 41 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock valued at $501,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on JNJ. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Weiss Ratings raised Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Leerink Partners raised Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 target price on the stock in a research report on Wednesday, May 13th. Finally, Guggenheim raised their target price on Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $272.83.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $275.63 on Thursday. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $281.07. The company has a market cap of $664.25 billion, a PE ratio of 31.94, a P/E/G ratio of 2.59 and a beta of 0.24. The stock has a 50 day simple moving average of $260.90 and a 200-day simple moving average of $244.61. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same period last year, the firm earned $2.77 EPS. The firm's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's payout ratio is currently 62.11%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is owned by company insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: UBS initiated coverage of Johnson & Johnson (JNJ) with a Buy rating and a $320 target, reflecting expectations that the company’s pharmaceutical pipeline can support stronger growth. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: Healthcare stocks broadly moved higher, with the NYSE Healthcare Index gaining 0.7%, creating a favorable backdrop for JNJ and other defensive healthcare names. Sector Update: Healthcare Stocks Advance Wednesday
• Positive Sentiment: Management will participate in a Deutsche Bank Healthcare Summit fireside chat on September 17. The event could provide additional commentary on the drug pipeline, growth outlook and capital allocation, although no new financial guidance was announced. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source